SI3883606T1 - Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23 - Google Patents

Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23

Info

Publication number
SI3883606T1
SI3883606T1 SI201930606T SI201930606T SI3883606T1 SI 3883606 T1 SI3883606 T1 SI 3883606T1 SI 201930606 T SI201930606 T SI 201930606T SI 201930606 T SI201930606 T SI 201930606T SI 3883606 T1 SI3883606 T1 SI 3883606T1
Authority
SI
Slovenia
Prior art keywords
antibody
safe
ulcerative colitis
effective method
treating ulcerative
Prior art date
Application number
SI201930606T
Other languages
English (en)
Inventor
Jewel Johanns
Katherine Li
Colleen Marano
Richard Strauss
Hongyan Zhang
Omoniyi Adedokun
Christopher O'brien
Kimberly Shields-Tuttle
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69885324&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3883606(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of SI3883606T1 publication Critical patent/SI3883606T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SI201930606T 2018-09-24 2019-09-24 Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23 SI3883606T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862735501P 2018-09-24 2018-09-24
US201862769818P 2018-11-20 2018-11-20
US201962895774P 2019-09-04 2019-09-04
EP19867085.3A EP3883606B9 (en) 2018-09-24 2019-09-24 Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
PCT/IB2019/058098 WO2020065532A1 (en) 2018-09-24 2019-09-24 Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody

Publications (1)

Publication Number Publication Date
SI3883606T1 true SI3883606T1 (sl) 2023-10-30

Family

ID=69885324

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930606T SI3883606T1 (sl) 2018-09-24 2019-09-24 Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23

Country Status (22)

Country Link
US (2) US10961307B2 (sl)
EP (1) EP3883606B9 (sl)
JP (3) JP7359845B2 (sl)
KR (2) KR20210064315A (sl)
CN (1) CN113164596A (sl)
AU (8) AU2019346134B2 (sl)
BR (1) BR112021005467A2 (sl)
CA (2) CA3160103A1 (sl)
DK (2) DK3883606T5 (sl)
ES (1) ES2959463T3 (sl)
FI (2) FI13575Y1 (sl)
HR (1) HRP20230886T1 (sl)
HU (1) HUE063462T2 (sl)
IL (1) IL281642A (sl)
LT (1) LT3883606T (sl)
MD (1) MD3883606T3 (sl)
MX (1) MX2021003411A (sl)
PL (1) PL3883606T3 (sl)
PT (1) PT3883606T (sl)
RS (1) RS64552B9 (sl)
SI (1) SI3883606T1 (sl)
WO (1) WO2020065532A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
WO2021074897A2 (en) * 2019-10-18 2021-04-22 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
AU2021308574A1 (en) * 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
EP4188443A1 (en) * 2020-07-30 2023-06-07 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
US20220102008A1 (en) * 2020-09-30 2022-03-31 Genentech, Inc. Methods and systems for placebo response modeling
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
CN117940163A (zh) * 2021-07-26 2024-04-26 阿瓦洛治疗公司 用抗light抗体治疗溃疡性结肠炎的方法

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3588239T3 (de) 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
ATE140731T1 (de) 1988-01-11 1996-08-15 Xoma Corp Plasmidvektor mit pectatlyase-signalsequenz
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
CA2441636A1 (en) 1988-11-10 1990-05-10 The Wistar Institute Of Anatomy And Biology Natural killer stimulatory factor
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
EP0433827B1 (en) 1989-12-22 1998-03-04 F. Hoffmann-La Roche Ag Cytotoxic lymphocyte maturation factor
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
CA2089362C (en) 1990-08-24 2000-11-21 William D. Huse Methods of synthesizing oligonucleotides with random codons
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1992011272A1 (en) 1990-12-20 1992-07-09 Ixsys, Inc. Optimization of binding proteins
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
WO1994018219A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE4315127A1 (de) 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
ES2161883T3 (es) 1994-04-22 2001-12-16 Corixa Corp Compuestos y metodos para la estimulacion y aumento de las respuestas inmunes protectoras y la produccion de il-2.
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19624387C2 (de) 1996-06-19 1999-08-19 Hatz Motoren Kaltstartvorrichtung
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AU6150498A (en) 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
AU8691398A (en) 1997-08-04 1999-02-22 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
DK1019021T4 (da) 1997-09-29 2013-01-07 Novartis Ag Stabiliserede præparater til anvendelse i inhalatorer med afmålt dosis
DK1049717T3 (da) 1998-01-23 2007-07-30 Hoffmann La Roche Antistoffer mod human IL-2
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
JP3579355B2 (ja) 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2669512A1 (en) 1999-03-25 2000-09-28 Abbott Gmbh & Co. Kg Human antibodies that bind human il-12 and methods for producing
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2002079255A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2004101750A2 (en) 2003-05-09 2004-11-25 Centocor, Inc. IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
NZ596992A (en) 2005-06-30 2013-07-26 Abbott Lab Il-12/p40 binding proteins
WO2009114040A2 (en) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
US8853365B2 (en) * 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
EP3349854A4 (en) 2015-09-17 2019-04-03 Amgen Inc. PREDICTING THE CLINICAL RESPONSE TO IL23 ANTAGONISTS WITH IL23 PATIENT BIOMARKERS
US11220541B2 (en) * 2015-12-22 2022-01-11 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
AU2017376807A1 (en) * 2016-12-14 2019-06-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device

Also Published As

Publication number Publication date
DK202300038Y3 (da) 2024-04-24
EP3883606A1 (en) 2021-09-29
AU2019346134B2 (en) 2023-01-12
AU2023100041A4 (en) 2023-06-22
HRP20230886T1 (hr) 2023-11-24
AU2024100006A4 (en) 2024-03-21
FI3883606T3 (fi) 2023-09-07
AU2023100042B9 (en) 2024-01-18
EP3883606A4 (en) 2022-07-06
FI13575Y1 (fi) 2024-03-26
MD3883606T3 (ro) 2024-03-31
DK3883606T5 (da) 2024-01-02
AU2023100041B4 (en) 2024-01-04
US20210171622A1 (en) 2021-06-10
JP7359845B2 (ja) 2023-10-11
AU2023100042A4 (en) 2023-06-22
PL3883606T3 (pl) 2023-11-27
JP2023052036A (ja) 2023-04-11
AU2024100017A4 (en) 2024-04-18
JP2022500474A (ja) 2022-01-04
MD3883606T2 (ro) 2023-12-31
CA3160103A1 (en) 2020-04-02
CA3113837C (en) 2022-07-12
DK3883606T3 (da) 2023-10-09
US20200095315A1 (en) 2020-03-26
RS64552B1 (sr) 2023-10-31
RS64552B9 (sr) 2024-02-29
BR112021005467A2 (pt) 2021-06-22
LT3883606T (lt) 2023-09-11
EP3883606B1 (en) 2023-07-12
KR20230148273A (ko) 2023-10-24
PT3883606T (pt) 2023-10-18
CA3113837A1 (en) 2020-04-02
MX2021003411A (es) 2021-06-15
IL281642A (en) 2021-05-31
AU2024100007A4 (en) 2024-03-21
HUE063462T2 (hu) 2024-01-28
JP7481423B2 (ja) 2024-05-10
AU2023100042B4 (en) 2024-01-04
AU2024100016A4 (en) 2024-04-18
CN113164596A (zh) 2021-07-23
AU2019346134A1 (en) 2021-04-01
KR20210064315A (ko) 2021-06-02
EP3883606B9 (en) 2023-10-04
DK202300038U1 (da) 2023-09-20
US10961307B2 (en) 2021-03-30
AU2023201217A1 (en) 2023-03-30
ES2959463T3 (es) 2024-02-26
JP2023162273A (ja) 2023-11-08
WO2020065532A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
IL281642A (en) A safe and effective method for the treatment of ulcerative colitis with an anti-IL12/IL23 antibody
IL273475A (en) A safe and effective method to treat lupus with an anti-IL12/IL23 antibody
IL275096A (en) Antibodies against PD-1 and treatment methods
IL255690A (en) Method and application environment for safe execution of program instructions
IL274272A (en) A safe and effective method for treating psoriatic arthritis with a specific anti-IL23 antibody
IL265666A (en) A safe and effective method for the treatment of eczema with a specific anti-il23 antibody
SG11201705584VA (en) Anti-c5 antibodies and methods of use
IL277514A (en) Methods for treating ulcerative colitis
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL288496A (en) A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-il23 antibody
IL266518A (en) Methods for the treatment of pulmonary hypertension with combinations of Relinfag and other substances
EP3793521A4 (en) SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
NO20200626A1 (en) Safety Valve Coupling and Method of Manufacturing Valve
GB201710441D0 (en) Sealing and shimming of structural joints
SG10201507971VA (en) Joint Assemblies And Method Of Inspecting Thereof
IL292215A (en) A safe and effective method for treating ulcerative colitis with an anti-il12/il23 antibody
EP3897722A4 (en) SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
PL3565380T3 (pl) Urządzenie i metoda ogrzewania mikrofalowego z technologią inwerterową
EP4103606A4 (en) SAFE AND EFFECTIVE METHOD FOR TREATING ULCERATIVE COLITIS WITH ANTI-IL-12/IL23 ANTIBODIES
ZA201807271B (en) A closure with foamed region and method of forming said closure
GB2578614B (en) Coupling assembly with valves and method of coupling
GB2538254B (en) Processing method of radiation-tainted water and sealing processing method of nuclear plant
MA55140A (fr) Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23
PL3491426T3 (pl) System kontroli ze źródłem promieniowania oraz sposób
PL3290543T3 (pl) Sposób obróbki powierzchni metalowych kompozycją wodną i kompozycja wodna